Guenther Steger
Overview
Explore the profile of Guenther Steger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papakonstantinou A, Matikas A, Bengtsson N, Malmstrom P, Hedayati E, Steger G, et al.
Cancer
. 2019 Dec;
126(6):1175-1182.
PMID: 31851385
Background: Dose-dense (DD) adjuvant chemotherapy improves outcomes in early breast cancer (BC). However, there are no phase 3 randomized data to inform on its combination with trastuzumab for patients with...
2.
Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, et al.
Eur J Cancer
. 2017 Sep;
85:133-145.
PMID: 28923573
Aim: The Neoadjuvant PI3K inhibition in HER2 OverExpressing Breast cancEr (NeoPHOEBE) trial evaluated the efficacy and safety of buparlisib, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, plus trastuzumab and paclitaxel as neoadjuvant...
3.
Unseld M, Scheithauer W, Weigl R, Kornek G, Stranzl N, Bianconi D, et al.
J Gastrointest Oncol
. 2016 Aug;
7(4):588-94.
PMID: 27563449
Background: Advanced cholangiocellular carcinoma has a poor prognosis with limited therapeutic options. Nab-paclitaxel has recently been described to be beneficial in metastatic pancreatic cancer improving overall and progression free survival...
4.
Exner R, Sachet M, Arnold T, Zinn-Zinnenburg M, Michlmayr A, Dubsky P, et al.
Cancer Med
. 2016 Jul;
5(9):2350-8.
PMID: 27457217
The response to neoadjuvant chemotherapy in breast cancer patients is usually assessed by pCR and RCB score. However, the prognostic value of these parameters is still in discussion. We showed...
5.
Freyer G, Kalinka-Warzocha E, Syrigos K, Marinca M, Tonini G, Ng S, et al.
Med Oncol
. 2015 Aug;
32(10):236.
PMID: 26315712
Febrile neutropenia (FN) is a potentially fatal complication of chemotherapy. This prospective, observational study describes physicians' approaches toward assessing FN risk in patients receiving chemotherapy regimens with an intermediate (10-20 ...
6.
Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, et al.
J Transl Med
. 2013 Dec;
11:307.
PMID: 24330813
Background: Monoclonal antibodies (mAb), such as trastuzumab are a valuable addition to breast cancer therapy. Data obtained from neoadjuvant settings revealed that antibody-dependent cell-mediated cytotoxicity (ADCC) is a major mechanism...
7.
Arnold T, Michlmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, et al.
Eur J Clin Invest
. 2013 Feb;
43(3):286-91.
PMID: 23410002
Background: The response of breast cancer patients to neoadjuvant chemotherapy (NCT) is highly heterogeneous, and reliable predictive instruments remain to be defined. High-mobility group box-1 (HMGB-1) protein is a cell...
8.
Gnant M, Blaha P, Dubsky P, Exner R, Fitzal F, Sporn E, et al.
Ther Adv Med Oncol
. 2011 Jul;
1(3):123-36.
PMID: 21789117
Recent advances in the treatment of early breast cancer have improved clinical outcomes and prolonged survival, especially in women with endocrine-responsive disease. However, cancer therapies including cytotoxic chemotherapy, ovarian suppression,...
9.
Fitzal F, Mittlboeck M, Steger G, Bartsch R, Rudas M, Dubsky P, et al.
Ann Surg Oncol
. 2011 Jul;
19(2):519-26.
PMID: 21743980
Introduction: Our study aims to determine whether patients with lobular-type breast cancer have significantly improved rates of breast conservation (BCT) after neoadjuvant chemotherapy (nCT). Methods: Patients who received nCT and...
10.
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al.
Lancet Oncol
. 2011 Jun;
12(7):631-41.
PMID: 21641868
Background: Analysis of the Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) at 48 months' follow-up showed that addition of zoledronic acid to adjuvant endocrine therapy significantly improved disease-free...